The aim of this study was to investigate the potential mechanism by which PCSK9 inhibition reduces the occurrence of ischemic stroke, and the researchers hypothesized that PCSK9 inhibition reduces the incidence of stroke by reducing atherosclerotic plaque, which may be of particular benefit to patients with intracranial atherosclerosis, who are at the highest risk of recurrent stroke of all stroke mechanisms. Here, PCSK9 is linked to stroke disorder.